Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9004436 | 0.94 | HDAC2 (0.50) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL14606179 | 0.83 | HDAC2 (0.55) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL9004448 | 0.82 | CES2 (0.33) | HDAC2HDAC4HDAC8HDAC6HDAC1 | |
| SCHEMBL4104945 | 0.80 | — | — | |
| SCHEMBL28593099 | 0.80 | HDAC2 (0.44) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL29035906 | 0.78 | HDAC2 (0.59) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL28986665 | 0.78 | HDAC2 (0.59) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL19115944 | 0.78 | HDAC2 (0.47) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL20262297 | 0.77 | HDAC2 (0.46) | HDAC2HDAC4HDAC8HDAC6CTSK | |
| SCHEMBL28422617 | 0.76 | HDAC2 (0.49) | HDAC2HDAC4HDAC8HDAC6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-11274093-B2 | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-4028279-A | Novel fragrance compositions containing 2,6,6 trimethyl-1-cyclohexen-1-yl acetaldehyde and phenyl C6 ketone | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | HDAC2 1013/4885HDAC4 2320/4885HDAC8 1316/4885 |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | MLLT1, MEN1, BMI1 | HDAC2 593/4885HDAC4 1094/4885HDAC8 510/4885 |
| US-11274093-B2 | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | KRAS, NRAS, HRAS | HDAC2 1644/4885HDAC4 3083/4885HDAC8 1567/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | HDAC2 1120/4885HDAC4 652/4885HDAC8 250/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | HDAC2 1013/4885HDAC4 2320/4885HDAC8 1316/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HDAC2 2129/4885HDAC4 1741/4885HDAC8 1458/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | HDAC2 1206/4885HDAC4 1664/4885HDAC8 1603/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HDAC2 2773/4885HDAC4 2091/4885HDAC8 947/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | HDAC2 1013/4885HDAC4 2320/4885HDAC8 1316/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | HDAC2 1013/4885HDAC4 2320/4885HDAC8 1316/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | HDAC2 3134/4885HDAC4 3919/4885HDAC8 3107/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HDAC2 2129/4885HDAC4 1741/4885HDAC8 1458/4885 |
| US-20210317127-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | HDAC2 2459/4885HDAC4 2006/4885HDAC8 1689/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HDAC2 264/4885HDAC4 946/4885HDAC8 566/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HDAC2 2129/4885HDAC4 1741/4885HDAC8 1458/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | HDAC2 2129/4885HDAC4 1741/4885HDAC8 1458/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | HDAC2 2742/4885HDAC4 3643/4885HDAC8 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.